Pfiz­er ex­ecs con­fi­dent­ly tap their top 10 block­busters-to-be. But what are the chances of sur­viv­ing PhI­II, let alone hit­ting these big peak sales es­ti­mates?

Pfiz­er’s top ex­ec­u­tive team doesn’t lack for con­fi­dence.

Where many Big Phar­mas would be re­luc­tant to put a peak sales fig­ure on their late-stage drugs, Pfiz­er CEO Al­bert Bourla has shrugged off the usu­al dif­fi­dence to out­line where the phar­ma gi­ant ex­pects to get $15 bil­lion-plus.

The list, out­lined this week dur­ing their in­vestor pre­sen­ta­tions, is topped by 3 drugs in the $3 bil­lion-plus peak sales cat­e­go­ry. They are:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER